S
Sahajanand Medical Technologies
SMT is a leading developer and manufacturer of minimally invasive coronary stent systems, with one of the broadest product portfolio in the industry
About Sahajanand Medical Technologies
SMT is a prominent global developer and manufacturer specializing in minimally invasive cardiovascular devices. The company focuses on creating advanced medical devices for coronary and structural heart treatments, as well as closure devices. SMT serves healthcare providers and cardiologists worldwide, including regions like Australia, New Zealand, China, Europe, and the United States. Operating in the medical device market, SMT's business model revolves around continuous innovation and upgrading its product portfolio to meet evolving healthcare needs. The company generates revenue through the sale of its sophisticated medical devices, which are designed to improve patient outcomes and save lives. SMT's commitment to advancing patient care is evident through its state-of-the-art products and ongoing clinical trials, such as the TALENT Randomized Controlled Trial of the Supraflex stent.
Source: Dealroom company dataAt a glance
- Founded
- 1998
- Headquarters
- India
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
- SCSamara Capital
Morgan Stanley
Unigestion
TR Capital
StepStone Group
Axiom Asia Private Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sahajanand Medical Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sahajanand Medical Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.